Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinically significant" new drug interactions].

U Fuhr1

  • 1Klinische Pharmakologie, Universität zu Köln. uwe.fuhr@medizin.uni-koeln.de

Medizinische Klinik (Munich, Germany : 1983)
|June 14, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enzyme autoinduction by mitotane supported by population pharmacokinetic modelling in a large cohort of adrenocortical carcinoma patients.

European journal of endocrinology·2018
Same author

Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.

Cancer chemotherapy and pharmacology·2015
Same author

Pharmacokinetics and pharmacodynamics of moist inhalation epinephrine using a mobile inhaler.

European journal of clinical pharmacology·2013
Same author

Factors influencing the pharmacokinetics of prophylactic posaconazole oral suspension in patients with acute myeloid leukemia or myelodysplastic syndrome.

European journal of clinical pharmacology·2012
Same author

Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.

European journal of clinical pharmacology·2011
Same author

Assessment of activity levels for CYP2D6*1, CYP2D6*2, and CYP2D6*41 genes by population pharmacokinetics of dextromethorphan.

Clinical pharmacology and therapeutics·2010
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

Medizinische Klinik (Munich, Germany : 1983)·2020
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2016
Same journal

[Not Available].

Medizinische Klinik (Munich, Germany : 1983)·2014
See all related articles

Drug interactions are common but rarely cause adverse effects. Evaluating clinical relevance is challenging, so avoid stopping safe drug combinations unless alternatives exist.

Area of Science:

  • Pharmacology
  • Clinical Pharmacy
  • Drug Safety

Context:

  • Drug interactions are frequent in clinical practice.
  • Adverse effects from drug interactions represent a small proportion of all adverse events.
  • Reproducible methods for evaluating the clinical relevance of drug interactions are needed.

Purpose:

  • To address the lack of reproducible evaluation methods for the clinical relevance of drug interactions.
  • To discuss the utility of drug interaction potential assessment within drug classes.
  • To provide guidance on managing drug combinations with interaction risks.

Summary:

  • Drug interactions are common, but their adverse effects are infrequent, highlighting a gap in clinical relevance assessment.
  • Accurate prediction of drug interaction potential is possible through comparative drug class investigations.

Related Experiment Videos

  • Therapeutically valuable drug combinations with interaction risks should generally be maintained if no equivalent alternatives are available.

    • Impact:

    • Guides clinical decision-making regarding drug combinations with potential interactions.
    • Highlights the importance of assessing clinical relevance over mere interaction potential.
    • Informs healthcare professionals on managing specific drug interactions, including those with SSRIs, statins, and protease inhibitors.